An Mpox surge across Africa is underway, with Clade I variants emerging. The EMA has given favorable scientific advice for the Geo-MVA vaccine candidate, amidst heavy impacts in DRC and Malawi.
2 reports, 1 independent
Updated Jul 29
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
An Mpox surge across Africa is underway, with Clade I variants emerging. The EMA has given favorable scientific advice for the Geo-MVA vaccine candidate, amidst heavy impacts in DRC and Malawi.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- GeoVax Labs, based in Atlanta, announced its vaccine addresses outbreaks in Central Africa following favorable EMA input.Sub-event
- Brincidofovir is being evaluated as an antiviral treatment for Mpox infections in the DRC, following a WHO PHEIC declaration.Sub-event
Mpox surge in Africa impacts DRC and Malawi; EMA assesses GeoVax candidate.1 source
Keep exploring
The entities involved
-
Africa
continent
-
GeoVax
biotechnology company
Nothing else this week.
-
Clade
Nothing else this week.
-
Democratic Republic of the Congo
country in Central Africa
Related events
Coverage
Newest first; wire copies grouped- NewMediaWireGeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation EMA Scientific Guidance, Global Surge in Clade I Mpox, and Aid Shortfalls
- NewMediaWireGeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand European Medicines Agency Supports Streamlined Development Pathway for GEO-MVA Vaccine Candidate via a